500 related articles for article (PubMed ID: 32253744)
1. Precision Cardio-Oncology: a Systems-Based Perspective on Cardiotoxicity of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors.
Brown SA; Ray JC; Herrmann J
J Cardiovasc Transl Res; 2020 Jun; 13(3):402-416. PubMed ID: 32253744
[TBL] [Abstract][Full Text] [Related]
2. Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities.
Guha A; Armanious M; Fradley MG
Trends Cardiovasc Med; 2019 Jan; 29(1):29-39. PubMed ID: 29910109
[TBL] [Abstract][Full Text] [Related]
3. Personalized medicine in cardio-oncology: the role of induced pluripotent stem cell.
Sayed N; Ameen M; Wu JC
Cardiovasc Res; 2019 Apr; 115(5):949-959. PubMed ID: 30768178
[TBL] [Abstract][Full Text] [Related]
4. Cardiac Toxicity of Immune Checkpoint Inhibitors: Cardio-Oncology Meets Immunology.
Varricchi G; Galdiero MR; Tocchetti CG
Circulation; 2017 Nov; 136(21):1989-1992. PubMed ID: 29158212
[No Abstract] [Full Text] [Related]
5. The Role of Biomarkers in Cardio-Oncology.
Ananthan K; Lyon AR
J Cardiovasc Transl Res; 2020 Jun; 13(3):431-450. PubMed ID: 32642841
[TBL] [Abstract][Full Text] [Related]
6. Cancer therapy-induced cardiovascular toxicity: old/new problems and old drugs.
Beyer AM; Bonini MG; Moslehi J
Am J Physiol Heart Circ Physiol; 2019 Jul; 317(1):H164-H167. PubMed ID: 31172808
[TBL] [Abstract][Full Text] [Related]
7. Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery.
Bellinger AM; Arteaga CL; Force T; Humphreys BD; Demetri GD; Druker BJ; Moslehi JJ
Circulation; 2015 Dec; 132(23):2248-58. PubMed ID: 26644247
[TBL] [Abstract][Full Text] [Related]
8. Preclinical approaches to assess potential kinase inhibitor-induced cardiac toxicity: Past, present and future.
Yang B; Papoian T
J Appl Toxicol; 2018 Jun; 38(6):790-800. PubMed ID: 29369373
[TBL] [Abstract][Full Text] [Related]
9. [Mechanisms of cardiotoxicity of oncological therapies].
Lehmann LH; Fröhling S
Internist (Berl); 2020 Nov; 61(11):1132-1139. PubMed ID: 33034675
[TBL] [Abstract][Full Text] [Related]
10. Cardiac Imaging in Oncology Patients in Europe: a Model for Advancement of CV Safety and Development of Comprehensive CV Care.
López-Fernández T
J Cardiovasc Transl Res; 2020 Jun; 13(3):490-494. PubMed ID: 32583314
[TBL] [Abstract][Full Text] [Related]
11. Metabolic Imaging in Cardio-oncology.
Tong D; Zaha VG
J Cardiovasc Transl Res; 2020 Jun; 13(3):357-366. PubMed ID: 31696405
[TBL] [Abstract][Full Text] [Related]
12. Heart Failure With Targeted Cancer Therapies: Mechanisms and Cardioprotection.
Hahn VS; Zhang KW; Sun L; Narayan V; Lenihan DJ; Ky B
Circ Res; 2021 May; 128(10):1576-1593. PubMed ID: 33983833
[TBL] [Abstract][Full Text] [Related]
13. Clinical Practice and Research in Cardio-Oncology: Finding the "Rosetta Stone" for Establishing Program Excellence in Cardio-oncology.
Adusumalli S; Alvarez-Cardona J; Khatana SM; Mitchell JD; Blaes AH; Casselli SJ; O'Quinn R; Lenihan DJ
J Cardiovasc Transl Res; 2020 Jun; 13(3):495-505. PubMed ID: 32444945
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Models of Cancer Therapy-Associated Cardiovascular Toxicity: A Scientific Statement From the American Heart Association.
Asnani A; Moslehi JJ; Adhikari BB; Baik AH; Beyer AM; de Boer RA; Ghigo A; Grumbach IM; Jain S; Zhu H;
Circ Res; 2021 Jun; 129(1):e21-e34. PubMed ID: 33934611
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitors and cardiovascular toxicity.
Lyon AR; Yousaf N; Battisti NML; Moslehi J; Larkin J
Lancet Oncol; 2018 Sep; 19(9):e447-e458. PubMed ID: 30191849
[TBL] [Abstract][Full Text] [Related]
16. Brazilian cardio-oncology: the 10-year experience of the Instituto do Cancer do Estado de Sao Paulo.
Costa IBSDS; Bittar CS; Fonseca SMR; E Silva CMPD; Dos Santos Rehder MHH; Rizk SI; Cruz CBBV; Figueiredo CS; de A Andrade FT; Barberino LA; de S Costa FA; Machado LP; González TB; Almeida MPC; Fukushima JT; Kalil Filho R; Hajjar LA
BMC Cardiovasc Disord; 2020 Apr; 20(1):206. PubMed ID: 32345217
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular Toxicities in Pediatric Cancer Survivors.
Ryan TD; Nagarajan R; Godown J
Cardiol Clin; 2019 Nov; 37(4):533-544. PubMed ID: 31587793
[TBL] [Abstract][Full Text] [Related]
18. Modeling Precision Cardio-Oncology: Using Human-Induced Pluripotent Stem Cells for Risk Stratification and Prevention.
Perry TR; Roberts ML; Sunkara B; Maddula R; McLeish T; Gomez J; Lucas J; Rayan D; Patel S; Liang M; Bosnjak ZJ; Brown SA
Curr Oncol Rep; 2021 May; 23(7):77. PubMed ID: 33937943
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular toxicities associated with immune checkpoint inhibitors.
Hu JR; Florido R; Lipson EJ; Naidoo J; Ardehali R; Tocchetti CG; Lyon AR; Padera RF; Johnson DB; Moslehi J
Cardiovasc Res; 2019 Apr; 115(5):854-868. PubMed ID: 30715219
[TBL] [Abstract][Full Text] [Related]
20. Paediatric cardio-oncology: epidemiology, screening, prevention, and treatment.
Chow EJ; Leger KJ; Bhatt NS; Mulrooney DA; Ross CJ; Aggarwal S; Bansal N; Ehrhardt MJ; Armenian SH; Scott JM; Hong B
Cardiovasc Res; 2019 Apr; 115(5):922-934. PubMed ID: 30768157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
